A Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of IBI355 in Healthy Voluteers
Latest Information Update: 28 May 2025
At a glance
- Drugs IBI 355 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Innovent Biologics
Most Recent Events
- 21 May 2025 Status changed from active, no longer recruiting to completed.
- 18 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.